HIMS vs JNJ

Hims & Hers retains growth potential driven by its D2C telehealth platform and positioning in chronic care like GLP-1s, evidenced by 59% YoY FY25 revenue growth and 2.5 million subscribers. However, the investment thesis for 10x growth within 3-5 years has significantly weakened since the last analysis. Intensified regulatory pressure on compounded GLP-1s directly threatens its fastest-growing seg...

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...